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 ORIGINAL ARTICLE 
 Effects of a pharmacist-led structured medication review in primary 
care on drug-related problems and hospital admission rates: 
a randomized controlled trial 
 CECILIA  LENANDER 1 ,  BIRGITTA  ELFSSON 2 ,  BIRGITTA  DANIELSSON 3 , 
 PATRIK  MIDL Ö V 1  &  JAN  HASSELSTR Ö M 3,4 
 1 Department of Clinical Sciences in Malm ö , Lund University, Malm ö , Sweden,  2 Apoteket AB, Hospital Pharmacy at 
S ö dersjukhuset, Stockholm, Sweden,  3 Stockholm County Drug and Therapeutic Committee, Stockholm County Council, 
Stockholm, Sweden, and  4 Centre for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska 
Institutet, Huddinge, Sweden 
 Abstract 
 Objective . To determine whether a pharmacist-led medications review in primary care reduces the number of drugs and the 
number of drug-related problems.  Design. Prospective randomized controlled trial.  Setting. Liljeholmen Primary Care 
Centre, Stockholm, Sweden.  Subjects . 209 patients aged    65 years with fi ve or more different medications.  Intervention . 
Patients answered a questionnaire regarding medications. The pharmacist reviewed all medications (prescription, non-
prescription, and herbal) regarding recommendations and renal impairment, giving advice to patients and GPs. Each patient 
met the pharmacist before seeing their GP. Control patients received their usual care.  Main outcome measures. Drug-related 
problems and number of drugs. Secondary outcomes included health care utilization and self-rated health during 12 months 
of follow-up.  Results. No signifi cant difference was seen when comparing change in drug-related problems between the 
groups. However , a signifi cant decrease in drug-related problems was observed in the intervention group (from 1.73 per 
patient at baseline to 1.31 at follow-up, p    0.05). The change in number of drugs was more pronounced in the interven-
tion group (p    0.046). Intervention group patients were not admitted to hospital on fewer occasions or for fewer days, 
and there was no signifi cant difference between the two groups regarding utilization of primary care during follow-up. 
Self-rated health remained unchanged in the intervention group, whereas a drop (p    0.02) was reported in the control 
group. This resulted in a signifi cant difference in change in self-rated health between the groups (p    0.047).  Conclusions. 
The addition of a skilled pharmacist to the primary care team may contribute to reductions in numbers of drugs and 
maintenance of self-rated health in elderly patients with polypharmacy. 
 Key Words:  Drug-related problems ,  elderly ,  general practice ,  medication review ,  pharmacist ,  primary care ,  Sweden 
leads to health care utilization, morbidity or mortal-
ity ” [6], and indicators of prescribing quality for drug 
treatment in the elderly have been developed by the 
Swedish National Board of Health and Welfare [7]. 
 Pharmacists included in health care teams in 
hospitals have helped lower the cost of drugs and 
reduce hospitalization [8 – 10]. Medication reviews 
for elderly patients with polypharmacy in assisted 
living facilities have produced favourable effects such 
as fewer falls [11]. 
 Introduction 
 Elderly patients with multiple diseases and polyphar-
macy risk suffering from drug-related problems 
(DRPs) [1 – 4], and a signifi cant proportion of hospi-
tal admissions in the elderly are due to adverse drug 
events (ADEs) [1]. A DRP is defi ned as any undesir-
able event experienced by a patient involving or 
suspected of involving drug therapy and actually or 
potentially interfering with a desired patient outcome 
[5]. The defi nition used in Sweden is  “ anything that 
 Correspondence: Cecilia Lenander, Department of Clinical Sciences in Malm ö , Lund University, Jan Waldenstr ö ms gata 35, SE-20502 Malm ö . E-mail: 
cecilia.lenander@med.lu.se 
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 In primary health care many different study 
methods have been used in investigations of effects 
on health care utilization or quality of life (QoL), but 
so far none has proven superior [12 – 19]. However, 
methods where the pharmacist is part of a team seem 
to give better results [17]. According to Beney et  al. 
more research is needed since many different meth-
ods are used, making it diffi cult to compare results 
and to identify the parts of the interventions that are 
successful [20]. 
 Aims 
 The primary aim of this study was to assess whether 
a structured, randomized, and controlled interven-
tion by a pharmacist at a primary health care centre 
would decrease the number of drugs and the number 
of DRPs. Secondary aims were to evaluate the impact 
on self-rated health and health care utilization. 
 Material and methods 
 Setting 
 The study was performed during a 15-month period 
at a primary care centre in Stockholm serving 24 000 
inhabitants. 
 Subjects 
 Subjects to be included were persons aged    65 years 
with fi ve or more medications who were already 
scheduled for an appointment with a GP. Patients 
who were not fl uent in Swedish, could not answer for 
themselves, or had participated in an earlier pilot 
study were excluded. For all patients fulfi lling the 
inclusion criteria, gender, age, and, when applicable, 
reason for exclusion, were recorded. 
 Study design 
 The study was a randomized controlled trial. We 
compared patients with a scheduled GP consultation 
who received normal care with patients who received 
preparatory structured pharmaceutical advice. 
 All patients fulfi lling the inclusion criteria were 
contacted by telephone (see Figure 1). Those who 
agreed to participate were sent a questionnaire 
addressing all their medications (prescription, non-
prescription, and herbal drugs) and DRPs and were 
then randomized. The intervention group met a 
pharmacist prior to the GP visit and the control 
group received normal care. After 12 months, all 
patients were contacted by telephone and were sent 
a new questionnaire. Control patients were offered a 
medication review after the conclusion of the trial. 
 The effect of the intervention was measured 12 
months after the intervention in terms of DRPs, 
utilization of medical services, and self-rated health. 
 Pharmacist intervention 
 The medication review was performed by a certifi ed 
geriatrics pharmacist (CL). The method had been 
tested in a pilot study (79 patients). It involved a 
standardized semi-structured protocol that was open 
for patients ’ questions and remarks. Computerized 
patient records were checked for prescriptions, drug 
indications, and plans for evaluation. Drugs and dos-
ages were evaluated to correlate with renal function, 
good practice [7], and the drug formulary [21]. 
A patient-centred technique was used, focusing on 
the patients ’ questionnaire answers to assess under-
standing of and concordance with drug treatment. 
The patients were also asked about prescribers other 
than their GP, and use of non-prescription and herbal 
drugs. Concluding pharmaceutical advice was given 
to patients and entered into the computerized patient 
record. 
 Drug-related problems 
 DRPs were classifi ed based on Beers ’ criteria [22] 
and the structure proposed by Strand et  al. [23] 
using a computer system. Information about DRPs 
was gathered from the questionnaires at baseline and 
after 12 months. Data were analysed by an indepen-
dent certifi ed geriatrics pharmacist (BE), blinded to 
patient group allocation. 
 Utilization of medical care 
 The utilization of medical care was measured as the 
number of contacts in outpatient care and hospital 
care during the 12 months following the interven-
tion. Data were extracted from the records of Stock-
holm County Council using social security numbers, 
which gave 100% data coverage. 
 The elderly are often prone to drug-related  •
morbidity due to multimorbidity, polyphar-
macy, and deteriorating organ function. 
Drug-related problems may cause hospital 
admissions. 
 The addition of a skilled pharmacist to the  •
primary care team may contribute to 
reductions in numbers of drugs and to 
maintaining self-rated health in elderly 
patients with polypharmacy. 
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 Self-rated health 
 Patients assessed their health by answering a single 
question on general self-rated health with the 
response options  “ very good ” ,  “ good ” ,  “ fair ” ,  “ bad ” , 
and  “ very bad ” [24]. 
 Statistical analysis 
 A power analysis was based on the pilot study. To 
detect a 25% change in DRPs with a power of 80% 
and an estimated dropout frequency of 10%, the 
sample size was calculated as 200. 
 Data are given as means with 95% confi dence 
intervals (CIs), unless otherwise stated. Differences 
within groups (before vs. after intervention) were 
analysed by Wilcoxon matched-pairs test. The Mann –
 Whitney U test was used to test differences between 
groups . The chi-squared test was used to test for dif-
ferences in the frequencies of diagnosis between 
groups. Differences in numbers of primary care 
visits, hospital admissions, and days hospitalized 
were analysed by Mann – Whitney U test as they did 
not fi t the Poisson distribution. 
 Results 
 Subjects 
 Between September 2004 and November 2005, 395 
persons fulfi lling the inclusion criteria were identi-
fi ed, of whom 186 were excluded (Figure 1). The 
remaining 209 persons were randomly assigned to 
the control or intervention group (Figure 1). Patient 
characteristics at baseline are given in Table I. The 
two groups were similar concerning age, sex, and 
Intervention
107 patients
Control
102 patients
186 excluded
63 could not be reached, 4 had dementia, 2 did not
speak Swedish and 117declined to participate
209 patients randomized
Wished to be
excluded 10
Wished to be
excluded 20
Pharmacist consultation
Returned Q#1
n = 97
Care as usual
Returned Q#1
n = 70
Returned Q#1 + Q#2
n =75
Physician consultation Physician consultation 
395 patients
identified
Care as usual
Did not return Q#1
n = 13
Returned Q#2 n = 79
Returned Q#1 + Q#2 n =66  
Letter sent to all participants with questionnaire (Q#1)
Letter sent to all participants with questionnaire (Q#2)
 Figure 1. Overview of study design, patient inclusion, and completion of questionnaires. 
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number of diagnoses. There was no signifi cant differ-
ence in the prevalence of chronic diagnoses between 
the groups, apart from for psychiatric disease 
(Table II). However, patients in the intervention 
group used a greater number of drugs (8.6 vs. 
7.4 drugs per patient, p    0.05). After 12 months 
there was a mean reduction in the number of drugs 
per patient in the intervention group (from 8.6 to 
7.9, p    0.05), but not in the control group, where a 
mean increase from 7.4 to. 7.5 (not signifi cant) was 
detected. The change in the number of drugs differed 
signifi cantly (p    0.046) between the groups. 
 Drug-related problems 
 DRPs were analysed in all patients returning both 
questionnaires (75 patients in the intervention group 
and 66 patients in the control group) (see Figure 1). 
Signifi cant changes were seen in the before-and-after 
comparison in the intervention group, but not in the 
control group (Table III). A between-group analysis 
of the change in number of DRPs revealed no sig-
nifi cant differences (p    0.72). The mean decrease in 
number of DRPs was 0.43 (95% CI 0.10, 0.75) in 
the intervention group and 0.27 ( – 0.02, 0.57) in the 
control group. The decrease in the intervention group 
was mainly due to a signifi cant improvement in 
compliance (p    0.048) (Table III). 
 Utilization of medical care 
 There was no signifi cant difference between the two 
groups regarding utilization of primary care during 
the 12-month follow-up period (Figure 2). Patients 
in the intervention group were admitted to hospital 
on fewer occasions compared with the control group 
(mean 1.7 vs. 2.7, median 1 vs. 2). The length of 
hospitalisation during the follow-up period was also 
lower in the intervention group compared with the 
control group (mean 12 vs. 18 days, median 6 vs. 
12.5 days). However, none of the observed differ-
ences were statistically signifi cant (Figure 2). 
 Self-rated health 
 On a 1 – 5 scale, there were no signifi cant differences 
between the groups at baseline (intervention group 
2.7 and control group 2.8) regarding self-rated 
health. Self-rated health remained unchanged in the 
intervention group, whereas it decreased signifi cantly 
(p    0.02) in the control group, resulting in a sig-
nifi cant difference in change in self-rated health 
between the groups (p    0.047). The mean change 
was 0.02 in the intervention group (95% CI  – 0.15, 
0.19) and 0.27 (0.06, 0.48) in the control group. 
 Estimated cost of the intervention 
 The pharmacist had booked 30 minutes for each 
consultation, but including time for preparation and 
follow-up, each patient required approximately two 
 Table I. Patient characteristics at baseline for included patients (n    209) and analysed patients (n    141). 
Intervention group Control group
All included patients 
(n    107)
All analysed patients 
(n    75)
All included patients 
(n    102)
All analysed patients 
(n    66)
Age (years) 79.0 (77.8, 80.2) 79.0 (77.6, 80.4) 79.7 (78.4, 81.1) 78.6 (76.8, 80.3)
Sex (% female) 65.4 67.5 68.6 68.9
Number of drugs per patient 8.5 (7.9, 9.1) 8.6 (7.8, 9.3) 7.4 (6.9, 8.0) * 7.4 (6.6, 8.2) * 
Diagnoses per patient 5.1 (4.7, 5.4) 5.1 (4.7, 5.5) 4.5 (4.2, 4.9) * 4.7 (4.2, 5.2)
 Notes: Data are given as means with 95% confi dence intervals.  * Signifi cant vs. intervention. 
 Table II. Prevalence of chronic diagnoses in 102 control 
group patients and 107 intervention group patients at 
baseline. 
Control group
 (n    102)
 %
Intervention group
 (n    107)
 %
Hypertension 61 67
Hyperlipidaemia 39 48
Diabetes 28 26
Ischaemic heart disease 40 40
Cardiac decompensation 15 26
Atrial fi brillation 16 20
Peripheral artery disease 13 8
Cerebrovascular disease 11 16
Thyroid disease 13 14
Polymyalgia rheumatica 10 8
Malignant disease 18 21
Pulmonary disease 21 18
Pernicious anaemia 22 23
Gastrointestinal disease 18 19
Osteoporosis 15 14
Psychiatric disease 23 12
Diseases of the urinary tract 14 12
Chronic pain 24 29
 Note: There was no signifi cant difference in the distribution of 
diagnoses between groups (p    0.113), apart from for psychiatric 
disease. 
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hours. The cost of implementing this intervention in 
everyday practice was estimated at  € 79 ( $ 106) per 
patient, based on the estimated total cost of one 
clinically trained, experienced pharmacist. 
 Discussion 
 This trial showed that a structured medication review 
with a specially trained pharmacist within a primary 
care framework may have reduced the number of 
drugs and prevented a decrease in self-rated health. 
No signifi cant between-group difference in change in 
number of DRPs was detected; a within-group reduc-
tion was seen in the intervention group, but not in 
the control group. No effect on hospital admissions 
was found. Reducing the number of drugs by medi-
cation reviews is in line with fi ndings in other studies 
[25,26]. 
 We found a mean of 1.73 DRPs per patient in 
the intervention group at baseline (control group 
1.37 DRPs per patient), which is less than in other 
studies [10,19,25,27,28]. This could be explained by 
patients having more severe illnesses and registration 
of potential drug problems, rather than only actual 
problems, in these other studies. The most common 
DRPs in our study were ADEs and compliance 
problems. In other studies, common problems were 
unnecessary drug therapy and need for additional 
therapy or increased dosages [10,19,26,28]. The dif-
ference could be explained by different populations 
in the studies, i.e. patients in hospitals compared 
with patients in primary care. 
 The changes in self-rated health were signifi cantly 
different between the groups in favour of the inter-
vention group. A few studies have measured the 
infl uence of interventions on QoL [18 – 20,26,29]. 
 Table III. Drug-related problems at baseline and 12 months after a pharmacist medication review in primary care patients, 
for those returning both questionnaires (n    141). 
At baseline 
per patient 95% CI
12 months 
after inclusion 
per patient 95% CI
Between-group 
comparison level 
of signifi cance
Within-group 
comparison  level 
of signifi cance
Control group (n    66)
DRPs 1 total 1.37 (1.07, 1.69) 1.11 (0.84, 1.37) n.s. n.s.
ADEs 2 0.53 (0.33, 0.73) 0.50 (0.34, 0.66) n.s.
Wrong drug 0.33 (0.16, 0.50) 0.33 (0.19, 0.47) n.s.
Compliance problems 0.21 (0.07, 0.31) 0.11 (0.02, 0.19) n.s.
Dosage too low 0.09 (0.02, 0.16) 0.11 (0.03, 0.18) n.s.
Dosage too high 0.12 (0.03, 0.21) 0.03 (  0.01, 0.07) n.s.
Need for additional therapy 0.05 ( – 0.01, 0.10) 0.00  –  – 
Unnecessary drug therapy 0.05 ( – 0.01, 0.10) 0.03 (  0.01, 0.07) n.s.
Intervention (n    75)
DRPs 1 total 1.73 (1.42, 2.05) 1.31 (1.02, 1.59) n.s p    0.02
ADEs 2 0.64 (0.46, 0.82) 0.52 (0.36, 0.68) n.s.
Wrong drug 0.32 (0.19, 0.45) 0.31 (0.18, 0.44) n.s.
Compliance problems 0.37 (0.22, 0.52) 0.21 (0.09, 0.33) p    0.048
Dosage too low 0.17 (0.08, 0.27) 0.12 (0.04, 0.20) n.s.
Dosage too high 0.17 (0.08, 0.27) 0.12 (0.04, 0.20) n.s.
Need for additional therapy 0.04 ( – 0.01, 0.09) 0.03 ( – 0.01, 0.07) n.s.
Unnecessary drug therapy 0.01 ( – 0.01, 0.04) 0.00  –  – 
 Notes:  1 DRP    drug-related problem;  2 ADE    adverse drug effect. 
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 Figure 2. Primary care visits and hospital admissions (number and duration in days) recorded in the control and intervention groups 
during one year. Data are shown as the median ( ♦ ) with 95% CI ( ▬ ) and mean ( ■ ) values. None of the investigated parameters showed 
a statistically signifi cant difference. n    141 patients (75 in the intervention group and 66 in the control group). 
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These studies used a more extensive instrument and 
did not show a signifi cant improvement as a result of 
the intervention. 
 Our fi ndings are in line with other fi ndings that 
medication reviews do not decrease health care uti-
lization [18,19,26]. Results of medication reviews are 
complicated to analyse. It is not known which part 
or combination of elements in the review plays the 
key role. Our intervention was based on one phar-
macist performing the medication reviews and did 
not include education of doctors or specifi ed time for 
team discussions, as did the studies of, for example, 
Krska et  al. [29] and Sorensen et  al. [19]. Our inter-
vention took place at a primary care centre, which 
gave the pharmacist access to full patient records, but 
limited the study to patients who actually visited 
the primary care centre. Another limitation is that 
withdrawal was uneven between the two groups, and 
that we do not have data concerning medications and 
DRPs for the patients who withdrew. Therefore we 
do not know if these patients differ from those who 
completed the study. With frail, older patients it is 
also diffi cult to choose the right follow-up time. 
We chose 12 months to avoid seasonal differences. 
However, 12 months is a long time and many things 
could have happened that would have infl uenced the 
results. 
 Cost-effectiveness is also diffi cult to assess. The 
mean total time spent by the pharmacist on each 
patient in our study was two hours, compared with 
20 – 140 minutes in other studies [10,29]. Studies 
including home visits [18,19] estimate that two 
hours is required for each home visit, not including 
preparation, discussion with the patient ’ s GP, and 
follow-up. According to Pacini et  al. [30], the prob-
ability of such interventions being cost-effective is 
low. The cost of medication reviews mainly depends 
on the time allotted and it is thus diffi cult to compare 
costs between studies. We were unable to show any 
savings in the form of fewer hospital admissions or 
less use of primary health care, since this study was 
powered to detect a reduction of 25% in DRPs and 
not reductions in health care utilization. 
 The study was conducted at a primary care cen-
tre in an area with many elderly inhabitants. The 
perspective was on the individual patient ’ s everyday 
drug use under normal circumstances, focusing on 
patients ’ understanding and possible problems (such 
as ADEs and interactions), rather than on problems 
arising in hospitals. The pharmacist was well inte-
grated in the work at the health care centre, and thus 
had the chance for day-to-day interaction with doc-
tors and other health care personnel. The key to 
achieving results lay in the pharmacist working with 
others within a clinical setting, rather than on their 
own. This is supported by many other studies 
[8,9,14,16]. 
 All parameters for the intervention group 
appeared to change in the right direction, i.e. number 
of drugs, DRPs, self-rated health, and health care 
utilization. This indicates that this might be a suitable 
model for primary care. The self-rated health data 
suggest that medication reviews have positive effects, 
perhaps improving patients ’ understanding of their 
drug regimen and thereby increasing compliance. 
 A larger study involving more patients could 
hopefully show an effect on this and on health care 
utilization. There is also a need for studies comparing 
different interventions for optimizing pharmacother-
apy in primary health care. 
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